Trial Profile
A Multi-centre, Randomised, Open-label, Cross-over Study to Explore Effectiveness, Safety, and Preference of a New Disposable Pen PDS290 Versus FlexPen in Subjects With Type 1 or Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Insulin aspart (Primary) ; Insulin detemir (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 27 Jan 2012 Official title amended as reported by ClinicalTrials.gov.
- 16 Oct 2009 Actual patient number changed from 256 to 255 added as reported by ClinicalTrials.gov.
- 01 Jul 2009 Actual patient number (256) added as reported by ClinicalTrials.gov.